Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Epidermolysis Bullosa
Interventions: SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more

Conditions: Esophageal Varices, Liver Cirrhoses, Bleeding Esophageal Varices, Upper Gastrointestinal Bleeding
Interventions: Octreotide; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Jacksonville, Florida • Chicago, Illinois • Columbus, Ohio + 5 more

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more

Conditions: Early Stage Parkinson's Disease
Interventions: Aplindore, Placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Miami Shores, Florida • Boston, Massachusetts • Hackensack, New Jersey + 1 more

Conditions: Pancreaticoduodenectomy
Interventions: robotic pancreaticoduodenectomy; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Charlotte, North Carolina

Conditions: Breast Surgery
Interventions: Standard of care treatment; Device
Lead sponsor: Stryker Endoscopy; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Jacksonville, Florida • Boston, Massachusetts

Conditions: Elbow, Tennis
Interventions: TenJet System; Device
Lead sponsor: HydroCision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Muskegon, Michigan • DuBois, Pennsylvania • Fort Worth, Texas

Conditions: Astrocytic Tumors
Interventions: Cabozantinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Encinitas, California • Pleasant Hill, California + 12 more

Conditions: Healthy
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pompe Disease
Interventions: duvoglustat, rhGAA; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 8 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Brolucizumab 6 mg, Panretinal photocoagulation laser; Biological · Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more

Conditions: Heart Failure, Congestive
Interventions: GSK716155, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Savannah, Georgia • Metairie, Louisiana • Auburn, Maine + 9 more

Conditions: Crohn's Disease
Interventions: Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Acute Limb Ischemia
Interventions: MST-188, Saline; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 4
States / cities: Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more

Conditions: Children and Adolescent With Type 2 Diabetes
Interventions: Exenatide Once Weekly, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more

Conditions: Urinary Bladder Neoplasms
Interventions: Durvalumab, Olaparib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more

Conditions: Multiple Sclerosis
Interventions: MRI Contrast; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone; Drug
Lead sponsor: Jacob Laubach, MD; Other
Eligibility: 75 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin); Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 73
States / cities: Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 58 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: eteplirsen; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 6 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more

Conditions: Pediculosis
Interventions: MALG (malathion) Treatment; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 6 Months to 24 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Bentonville, Arkansas • Jonesboro, Arkansas

Conditions: Alzheimer's Disease
Interventions: Placebo, CAD106; Biological
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more

Conditions: Open-Angle Glaucoma
Interventions: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT); Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more

Search by objective public record fields.

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

Observation of Perioperative Outcomes of Robotic Pancreaticoduodenectomy

PROspect Registry :Post Market Clinical Follow-up Study

Percutaneous US Guided Elbow Tenotomy With the TenJet HydroSurgery System

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Drug-drug Interaction Study

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Evaluation of MST-188 in Acute Lower Limb Ischemia

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Central Vein Sign in Multiple Sclerosis Extension Study

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma